|
1
|
Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.
|
J Cell Physiol
|
2013
|
1.14
|
|
2
|
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
|
J Cell Physiol
|
2013
|
1.04
|
|
3
|
Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro.
|
BMC Cancer
|
2014
|
0.94
|
|
4
|
Reversibility of regorafenib effects in hepatocellular carcinoma cells.
|
Cancer Chemother Pharmacol
|
2013
|
0.86
|
|
5
|
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
|
BMC Cancer
|
2014
|
0.83
|
|
6
|
KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material.
|
Anticancer Res
|
2010
|
0.83
|
|
7
|
Assessment of estrogen receptors and apoptotic factors in cryopreserved human ovarian cortex.
|
Syst Biol Reprod Med
|
2009
|
0.81
|
|
8
|
Involvement of estrogen receptor-related receptors in human ovarian endometriosis.
|
Fertil Steril
|
2011
|
0.81
|
|
9
|
Potential role of the steroid receptor pattern in the response of inoperable intra-abdominal desmoid to toremifene after failure of tamoxifen therapy.
|
Int J Colorectal Dis
|
2009
|
0.79
|
|
10
|
Modulation of Doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates.
|
Anticancer Agents Med Chem
|
2014
|
0.77
|